Q2 2025 Earnings Forecast for McKesson Co. (NYSE:MCK) Issued By Leerink Partnrs

McKesson Co. (NYSE:MCK) – Leerink Partnrs increased their Q2 2025 earnings per share estimates for McKesson in a research note issued on Monday, April 22nd. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $7.45 for the quarter, up from their prior forecast of $7.36. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for McKesson’s current full-year earnings is $27.59 per share. Leerink Partnrs also issued estimates for McKesson’s FY2025 earnings at $31.37 EPS.

Several other brokerages also recently weighed in on MCK. StockNews.com downgraded McKesson from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 4th. SVB Leerink initiated coverage on McKesson in a report on Monday, February 26th. They set an “outperform” rating and a $600.00 price target for the company. Citigroup raised their price target on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Barclays initiated coverage on McKesson in a report on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 price target for the company. Finally, Morgan Stanley raised their price target on McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a report on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $533.50.

McKesson Trading Up 0.7 %

Shares of McKesson stock opened at $535.56 on Tuesday. The firm has a market capitalization of $70.38 billion, a P/E ratio of 24.27, a P/E/G ratio of 1.43 and a beta of 0.45. The business has a fifty day simple moving average of $526.81 and a two-hundred day simple moving average of $488.48. McKesson has a 12 month low of $352.34 and a 12 month high of $543.00.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 EPS for the quarter, beating the consensus estimate of $7.05 by $0.69. The business had revenue of $80.90 billion during the quarter, compared to analyst estimates of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the firm posted $6.90 earnings per share.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 0.46%. McKesson’s dividend payout ratio is currently 11.24%.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Leann B. Smith sold 186 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the sale, the executive vice president now directly owns 1,511 shares in the company, valued at approximately $749,456. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Brian S. Tyler sold 3,473 shares of McKesson stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the transaction, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the transaction, the executive vice president now directly owns 1,511 shares in the company, valued at $749,456. The disclosure for this sale can be found here. Corporate insiders own 0.21% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Private Trust Co. NA lifted its position in shares of McKesson by 8.4% during the 1st quarter. Private Trust Co. NA now owns 1,691 shares of the company’s stock valued at $908,000 after buying an additional 131 shares in the last quarter. Patton Albertson Miller Group LLC lifted its holdings in McKesson by 2.2% in the 1st quarter. Patton Albertson Miller Group LLC now owns 17,900 shares of the company’s stock worth $9,610,000 after purchasing an additional 388 shares in the last quarter. V Square Quantitative Management LLC lifted its holdings in McKesson by 111.0% in the 1st quarter. V Square Quantitative Management LLC now owns 1,017 shares of the company’s stock worth $546,000 after purchasing an additional 535 shares in the last quarter. Newbridge Financial Services Group Inc. lifted its holdings in McKesson by 333.3% in the 1st quarter. Newbridge Financial Services Group Inc. now owns 65 shares of the company’s stock worth $35,000 after purchasing an additional 50 shares in the last quarter. Finally, HMS Capital Management LLC lifted its holdings in McKesson by 3.7% in the 1st quarter. HMS Capital Management LLC now owns 4,473 shares of the company’s stock worth $2,401,000 after purchasing an additional 161 shares in the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.